09/03/2026
HDSA is hosting a webinar featuring the Novartis clinical development team to share the latest updates on the INVEST-HD Phase 3 trial evaluating votoplam for Huntington’s disease.
The first study sites are now open in North America, with more expected to follow around the world. The trial aims to include about 770 participants across more than 30 countries.
In this recorded session, Dr. Beth Borowsky and Dr. Harry Ramos provide an overview of the study, share where things stand today, and outline what to expect as the trial continues to roll out.
We invite you to submit your questions for the Novartis team when you register.
Questions from the community will be addressed during the webinar.
Visit: https://hdsa-org.zoom.us/webinar/register/2617749901893/WN_X5HpkIPfQxG-3ePjj0hF_A #/registration to learn more